Keywords: kosan, next-gen, epothilone, impresses, cancer, models, california
Kosan's next-gen epothilone impresses in cancer models
Article | 23 April 2007
California, USA-based drugmaker Kosan Biosciences says that data from a preclinical trial of its next-generation epothilone, KOS-1803, indicate that it ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
